anti-CD3/anti-ofCS bispecific T-cell engager (Var2 Pharmaceuticals/University of Copenhagen/University of British Columbia)

N/A

Report date: 2026/03/19 16:58:21

Base Information

Drug Nameanti-CD3/anti-ofCS bispecific T-cell engager (Var2 Pharmaceuticals/University of Copenhagen/University of British Columbia)
Drug Alias NameV-aCD3vartumab-anti-CD3dual anti-oncofetal chondroitin sulfate/anti-CD3 bispecific mAb (Var2 Pharmaceuticals/University of Copenhagen/University of British Columbia)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers
Mechanisms of ActionT cell surface glycoprotein CD3 modulatorsT-cell receptor modulatorsChondroitin sulfate proteoglycans modulators
TargetsChondroitin sulfate proteoglycansT cell surface glycoprotein CD3T-cell receptor
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaDenmark
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesCopenhagen University Hospital, Hvidovre
China Registration ClassN/A

Develop Information

Active CompaniesVar2 Pharmaceuticals APSCopenhagen University Hospital, HvidovreThe University Of British Columbia
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A